Commonwealth Signs Agreement with FDA
Commonwealth to work with FDA to enhance use of analytic tools for proactively and strategically managing safety during drug approval and post market surveillance
Waltham, MA - Commonwealth Informatics, a leading provider of clinical and safety analytics products and services, today announced that it signed a new contract to support the use of advanced drug safety review tools at the FDA Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). The focus of the agreement is for Commonwealth to support the expansion of the use of the analytic suite of tools to help FDA manage their drug and product safety proactively and strategically in drug approval and post market surveillance.
The long-term objective of the project is to build on CDER’s and CBER’s present use of Oracle signal detection software and to expand its usage strategically. The expansion includes providing CDER safety reviewers with the ability to evaluate a wider spectrum of health information sources including spontaneous reports, electronic health records, clinical trials, product labeling, social media, biomedical citations, search logs, and chemical and biologic data. An increased capacity for supporting the modern regulatory review of medical products is an objective of FDA’s 21st Century regulatory review processes.
The near-term focus of the contract is to carry out an upgrade to the latest versions of the Empirica Suite tools the FDA is presently using and to provide enhanced support to the CDER and CBER user community. This support includes day-to-day on-site and remote training and assistance for end users, data curation and enhancement of data content and data feeds, support for related and add-on applications, and the provision of Subject Matter Expert (SME) services in the use of the tools.
“The Commonwealth team has both the technical expertise and domain knowledge needed to collaborate closely and effectively with the FDA on this project," said Geoffrey Gordon, Commonwealth Informatics President. “We look forward to working with FDA to help solve tactical challenges and deliver on strategic objectives that will improve the way safety data is analyzed.”
About Commonwealth
Commonwealth Informatics is a technology and services company with industry expertise in medical product safety and public health surveillance. Pharmaceutical and biotechnology companies, government agencies, and healthcare providers use Commonwealth’s products and services to assemble relevant data and answer complex clinical and safety analysis questions quickly and accurately. For more information, visit commoninf.com.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
